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It is well-known that quality, efficacy and safety have to be 
guaranteed for medicinal products, but the point is at which level these 
attributes have to be satisfied. Generally speaking, based on scientific 
expertise and progress of a specific period of time the regulatory 
framework defines the minimal level that has to be documented 
before reaching the market. A further question is if this level should 
be the same for all types of drugs considering that if no authorized 
drugs are available for a clinical indication or in a subpopulation, 
how a physician can safeguard patient’s right and health? Indeed, in 
an ideal world, all patients should be treated by drugs for which the 
maximum levels of efficacy, safety and quality have been granted after 
the evaluation of specific experimental data. Nevertheless, authorized 
medicinal products placed on the market do not cover all therapeutic 
needs; for instance, drugs for rare pathologies as well as suitable dosage 
forms or doses for paediatric population are not available. In the case of 
orphan medicines, the major obstacle to obtain market authorization is 
to prove their efficacy and safety since the conventional design used in 
clinical trials makes it difficult for this to be fully accomplished: there 
are too few patients, often geographically dispersed, and most of the 
time there is no other treatment available than the medicine under 
evaluation. This situation is even more complex when medicines are 
intended for the paediatric population, where ethical concerns have 
other implications [1-4]. Indeed, as many as half of all paediatric drug 
prescriptions were for either unlicensed medications or off-label use 
of licensed medications and 67% of paediatric patients received an 
unlicensed or off-label [5].
To meet the legitimate patients’ right to receive treatment, the 
physician can prescribe pharmacological treatments other than for 
which the marketed authorization has been granted in the following 
scenarios: off-label prescriptions; compounded medicinal products; 
compassion use of medicinal products; prescription of medicinal 
products authorized in foreign countries [6].
The efficacy of all such therapeutic alternatives has not been proved 
according to the requirements established by the regulatory framework 
and the physician has to choose the active pharmaceutical ingredient 
on the basis of good sound scientific reasoning. The most suitable 
medicinal products will be selected while considering availability, 
costs and local regulatory requirements. If none of these alternatives 
are pursued, the physician shall initiate a clinical trial which assure 
safety to a high level and that protocols are carried out within ethical 
guidelines.
To avoid misuses of unlicensed drugs, the Authorities have to 
regulate their use. Probably a case-by-case approach is essential in 
order to establish the minimum requirements to fulfil. Indeed, in the 
case of the off-label use of drugs with market authorization, the quality 
is not under discussion, while the risk/benefit assessment is duty bound 
to physicians or regulatory framework. For example, in Italy at least a 
clinical study of Phase II as to be concluded.
The compassionate use normally is well regulated in all Countries. 
Extemporaneous preparations require attention to the quality other 
than risk/benefit aspects. Indeed, GMPs are not fully applicable in 
compounding pharmacies and adapted guidelines are elaborated (e.g. 
PIC [7]) or under discussion.
Considering these issues, can we pose limitations to the use of these 
products? Can we make a positive list? Probably not, above all is the 
light of the multiplicity of situations and the continuous progress of 
science.
The Public Administration must safeguard patients’ right and 
health, evaluating the appropriateness of medical prescriptions. The 
physician is the one who has the knowledge and the tools to properly 
diagnose a pathology and, therefore, to select the most appropriate 
therapy. Obviously, to completely legitimate the patient’s right to be 
treated it would be highly desirable to increase the number of granted 
marketing authorizations or to stimulate clinical studies. Even if the 
legislator defined a specific set of rules, there will be inevitably the need 
to fill the gaps with unlicensed drugs.
The more rigid the rules, the higher the risk of not legitimating the 
patient’s right to be treated because a suitable medical product will not 
be available or cannot be prescribed.
The Public Administration should not limit a physician’s freedom 
to prescribe only on-label approved drugs in an attempt to avoid 
misuse. The physician and the pharmacist have to be trained to assess 
the risk associated with all concerns to treatment or not a patient with 
an unlicensed drug. The Committee of Ministers of the Council of 
Europe enabled recently a resolution for extemporary preparations [8].
To favour the physicians’ best practice and to support their 
choices, high-value information should be easily available. The Public 
Administration and agencies should develop a programme to ensure 
availability of data and public access to databases, after defining ad-
hoc levels of safety and efficacy. To facilitate the work and to avoid 
duplication of studies, investigators and centres with specific expertise 
should be linked together in research networks. An effort should be 
made to include as many results as possible of clinical trials carried out 
in non-profit-making institutions.
On the basis of high-value evidence national and/or international 
scientific committees should also establish a decisional tree to support 
physicians’ decision in prescribing drugs of any origins and to guide 
national health systems and health insurance schemes in the selection 
of reimbursable therapy or treatments.
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